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The current increment of invasive fungal infections and the availability of new broad-
spectrum antifungal agents has increased the use of these agents by non-expert
practitioners, without an impact on mortality. To improve efﬁcacy while minimizing pre-
scription errors and to reduce the high monetary cost to the health systems, the principles
of  pharmacokinetics (PK) and pharmacodynamics (PD) are necessary. A systematic review
of  the PD of antifungals agents was performed aiming at the practicing physician without
expertise in this ﬁeld. The initial section of this review focuses on the general concepts of
antimicrobial PD. In vitro studies, fungal susceptibility and antifungal serum concentrations
are  related with different doses and dosing schedules, determining the PD indices and the
magnitude required to obtain a speciﬁc outcome. Herein the PD of the most used antifungalandidiasis
spergillosis
drug classes in Latin America (polyenes, azoles, and echinocandins) is discussed.
©  2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an
open  access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
fungal infections has been rising, mainly of invasive candidia-ntroduction
nvasive fungal infections are currently an important cause
f morbidity and mortality, especially in immunosuppressed
atients and those admitted in intensive care units.1,2 Candida
pp. are the most frequent etiological agent of fungal infec-Please cite this article in press as: Gonzalez JM, et al. Antifungal pharm
http://dx.doi.org/10.1016/j.bjid.2016.09.009
ions in humans, ranking fourth among the etiologic agents
f bloodstream infections in the United States, with a mortal-
ty similar to septic shock. In Latin America, a higher incidence
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413-8670/© 2016 Sociedade Brasileira de Infectologia. Published by E
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)of candidemia has been reported compared to countries of the
northern hemisphere.3 Additionally, the diversity of climates
and habitats in Latin America leads to a higher incidence
of endemic mycoses, including histoplasmosis, paracoccid-
ioidomycosis, and coccidioidomycosis.4
In the last years, the incidence of healthcare-associatedacodynamics: Latin America’s perspective. Braz J Infect Dis. 2016.
sis and aspergillosis.5 There has also been an increased report
of non-albicans Candida infections, which display reduced sus-
ceptibility to antifungal drugs.6 Finally, the number of patients
lsevier Editora Ltda. This is an open access article under the CC
.
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with profound immunosuppression secondary to the treat-
ment of hematologic malignancies and organ transplantation
is growing, and it has been associated with the increase of
invasive fungal infections due to several genera of molds that
represent formidable diagnostic and therapeutic challenges.7
Despite the availability of effective antifungal drugs, mortal-
ity due to fungal infections remains high,8 a fact that has
prompted the search for new products and a better under-
standing of the pharmacology of these agents to optimize
therapy.
There are additional components in Latin America to the
“host-fungi-drug” triad that may alter the pharmacodynamics
(PD) with unknown impact on resistance. For economic and
political reasons, generics are extensively used despite their
unproven therapeutic equivalence and, in some cases, the
treatment must be stopped due to shortage in supply. More-
over, the pharmacokinetics (PK)/PD knowledge has not been
extensively introduced in the curriculum of medical schools
and related clinical medical education activities are limited,
mainly because PK and PD integrations may be seen as com-
plex and not practical. In consequence, the advancements on
the PD of antifungal have not been implemented as in other
regions of the world.
MethodsPlease cite this article in press as: Gonzalez JM, et al. Antifungal pharm
http://dx.doi.org/10.1016/j.bjid.2016.09.009
A literature search was performed in the PubMed/MEDLINE
database looking for clinical trials, journal articles or reviews
available in full-text, written in Spanish or English languages,
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Fig. 1 – Pharmacokinetics (PK), pharmacodynamics (PD) and PK/P
the concentration-time curve; Cmax, maximal concentration or pe
distribution. Pharmacodynamic parameters. Emax, maximum effec
of the Emax, a measure of potency. MIC, minimal inhibitory conce 6;x x x(x x):xxx–xxx
published from January 1962 to July 2015, including the
keywords: pharmacodynamics (PD), pharmacokinetics (PK),
antifungals, candidiasis, and aspergillosis. Papers about anti-
fungal therapy co-authored by the expert in the ﬁeld David R.
Andes, were also searched. Out of 140 papers identiﬁed the
authors selected the relevant papers about in vitro, in vivo, and
clinical PD of antifungal agents, mainly emphasizing on the
PK/PD concepts; to build a practical review for general physi-
cians, especially in developing countries. The references of the
selected papers were also used if the authors considered them
relevant for the review.
Review
General  concepts  of  antimicrobial  pharmacodynamics
The study of the PK and PD properties of any antimicro-
bial is based on the exposure-response relationship of the
drug and the infecting pathogen.9 This relationship can be
modeled (Fig. 1) by integrating a PK parameter (e.g., max-
imal concentration or Cmax, and area under the curve or
AUC) and a PD parameter related with the response expected
against the infecting microorganism (i.e., minimal inhibitory
concentration or MIC). The knowledge derived from these
integrations has facilitated the design of optimal drug regi-acodynamics: Latin America’s perspective. Braz J Infect Dis. 2016.
mens and potentially reduce toxicity and the development of
resistance.10
Classically, PK studies are about assessing absorption, dis-
tribution, metabolism, and elimination of drugs. The aim of
bjective is to
e the relation
n drug dose or
tration and the
se or effect. In
ti-infective
rmacology
s the study of
 drug action
gainst the
oorgainisms.
f T>MIC
fCmax/MIC
fAUC/MIC
Emax
ED50
MIC
 study PK/PDintex
D integration. Pharmacokinetic parameters. AUC, area under
ak; EHL, elimination half-life; Cl, clearance; Vd, volume of
t, a measure of efﬁcacy. ED50, effective dose to achieve 50%
ntration.
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K is to determine the time-concentration drug proﬁle in dif-
erent ﬂuids and the degree of penetration to different organs,
ecause the drug effect is expected to correlate with the con-
entration at the site of the infection. Once a drug is inside of
he human body, its movement  between compartments and
uids depends on factors such as the fraction of unbound
rug. For this reason, in addition to the total drug concentra-
ion, for PK studies it is necessary to determine the degree of
rotein binding as only unbound drug exerts pharmacological
ctivity.11
PD studies, on the other hand, have to do with the rela-
ion between the drug concentration at site of action and the
esponse or effect. In anti-infective pharmacology, PD studies
ntegrate the susceptibility of the microorganisms (measured
y the MICs) with the antimicrobial exposure (based on the
K data) and the observed effect or response. With this infor-
ation it is possible to estimate PD indices (or PK/PD index)
elated to efﬁcacy, as well as their level necessary for spe-
iﬁc therapeutic goals. For antifungal drugs, three PD indices
ave been described: (i) the fraction of the dosing interval
he free drug concentration is above the MIC  (fT>MIC); (ii) the
atio of the area under the concentration-time curve and the
IC  (fAUC/MIC); and (iii) the ratio of the maximum concen-
ration or peak and the MIC  (fCmax/MIC). During the last 15
ears, these indices have been used to design optimal anti-
ungal dosing regimens with known probability of success
long a wide range of MIC  and also to establish susceptibility
reakpoints.12,13
To elucidate the PK/PD index for each antifungal, in vitro
nd in vivo studies are necessary. The process begins with
n vitro susceptibility testing to determine the MIC under
eproducible conditions,14 followed by a PK study to esti-
ate the population parameters (clearance and volume of
istribution). The ﬁnal step is a dose-response experiment
o relate exposure with antimicrobial effect using drug frac-
ionation, that is, testing the same dose in multiple dosing
chedules (e.g. q1h, q3h, q6h, q8h, q12h, and q24h). At the
nd, the three indices mentioned before (fT>MIC, fCmax/MIC
nd fAUC/MIC) are plotted against the effect to determine
hich index exhibits the best correlation with efﬁcacy and
o estimate the level required to achieve a particular end-
oint (for instance, to obtain 50% of maximal efﬁcacy or
0% survival). Thus, for drugs driven by the fCmax/MIC index
concentration-dependent), the dosing strategy is to use large
oses with infrequent intervals, whereas for fT>MIC drugs
time-dependent) the optimal regimen would be smaller but
ore  frequent doses or even extended or continuous infusion.
n the case of drugs driven by fAUC/MIC, the key factor is the
otal amount of drug administered in 24 h, independently of
he dosing schedule used.
Another key factor to determine the PD indices is the per-
istent effect, i.e.,  the capacity of a drug to suppress the growth
f the fungus after the compound is fully removed from the
edium (the post-antifungal effect or PAFE), or after the con-
entration falls below the MIC  (sub-MIC PAFE).15 Drugs driven
y fCmax/MIC and fAUC/MIC exhibit prolonged PAFE whilst thePlease cite this article in press as: Gonzalez JM, et al. Antifungal pharm
http://dx.doi.org/10.1016/j.bjid.2016.09.009
T>MIC driven ones usually display short or no PAFE. The dura-
ion of the PAFE depends on the type of action (fungicidal or
ungistatic), the drug concentration and the pathogen being
reated. For example, the echinocandins are fungicidal and;x  x x(x x):xxx–xxx 3
exhibit long PAFE against Candida spp., while fungistatic and
devoid of PAFE against Aspergillus fumigatus.16
The systemic antifungal classes currently available are
polyenes, triazoles, echinocandins, and ﬂucytosine. For all
of them, the PK/PD indices have been determined both
in vitro and in vivo,17–21 and the results conﬁrmed by clini-
cal studies (Table 1), demonstrating that dose optimization to
attain PD targets leads to higher clinical efﬁcacy.22,23 Due to
limited availability of ﬂucytosine in developing countries, the
present review will focus on the PD of polyenes, triazoles, and
echinocandins.
Polyenes
This antifungal class includes amphotericin B deoxycholate
(AMBd) and the lipid formulations: lipid complex (AMBlc), col-
loidal dispersion (AMBcd), and liposomal (AMBl).
The mechanism of action requires its binding to the
ergosterol in the fungal membrane, altering the cellular
permeability and leading to cell death. All formulations of
AMB  display a concentration-dependent effect with prolonged
PAFE, and the driving PK/PD index is the fCmax/MIC.15,16,19,24
Dose fractionation studies with the neutropenic mouse
disseminated candidiasis (NMDC) model, conﬁrmed that the
fungicidal efﬁcacy of AMBd correlated with large, infrequent
doses; for instance, dosing AMBd every 72 h (q72h) achieved
maximal efﬁcacy with doses 5–7 times lower than q6h or q12h
schedules.19 For fungistatic and maximally fungicidal effects,
the Cmax/MIC were 2–4 and 10, respectively. Similarly, but in
the murine model of invasive pulmonary aspergillosis, q72h
dosing schedules also led to a larger reduction in the fungal
burden and longer survival of infected animals in comparison
with q8h or q24h; in this model, the Cmax/MIC required for
maximal efﬁcacy was 2.4.25
In the NMDC model, AMBd was 4.3- to 5.9-fold more  potent
than AMBlc and AMBl in a mg/kg basis.26 Similarly, in the
neutropenic-rabbit model of invasive pulmonary aspergillo-
sis, near-maximal antifungal activity was evident with AMBd
at 1 mg/kg/day and AMBlc and AMBl at 5 mg/kg/day.27 Thus, to
achieve the needed Cmax/MIC with lipid formulations in clin-
ical practice, the daily dose should be almost 5-times higher
than the dose of AMBd. In opposition to the narrow therapeu-
tic index of AMBd, the lipid formulations are signiﬁcantly less
toxic in relation to the dose of AMBd, speciﬁcally in terms of
electrolytic imbalance, azotemia, renal tubular acidosis, ane-
mia, and arrhythmias.28
Regarding the PK of polyenes, the concentration-time pro-
ﬁle of amphotericin is nonlinear but there are important
differences between AMBd and lipid formulations.29 AMBd is
extensively distributed to tissues such as liver, kidneys, spleen
and, in small quantities (<1%), to heart and brain, but clear-
ance (Cl) from these sites is so slow (38 ± 15 mL/h/kg) as it
takes more  than one week to clear a single dose. Additionally,
it has a volume of distribution (Vd) of 5 ± 3 L/kg and the protein
binding is very high (>95%).30,31 AMB  levels in cerebrospinal
ﬂuid and vitreous are null to minimal, therefore intrathecal oracodynamics: Latin America’s perspective. Braz J Infect Dis. 2016.
intravitreal administration is needed in selected cases.
The lipid vehicle in the other formulations of ampho-
tericin B alters the distribution and clearance of the drug.30,32
For example, as AMBlc is a complex of AMB  with lipid
ARTICLE IN PRESSBJID-655; No. of Pages 9
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Table 1 – Summary of the PK/PD indices and their required magnitude for efﬁcacy with antifungal drugs and
recommended goals for therapeutic drug monitoring (TDM).
Antifungal class Drug PK/PD index
driving the
efﬁcacy
Target to attain Preferred
dose
TDM goal
(trough con-
centrations in
mg/L) [79]
References
Polyenes
AMB
deoxycholate
fCmax/MIC
≥10 0.4–1 mg/kg IV
q24h
Not
recommended
18,  27
AMB lipid
complex
≥50  5 mg/kg IV q24h Not
recommended
25
AMB liposomal ≥50 3–5  mg/kg IV
q24h
Not
recommended
25
AMB colloidal
dispersion
≥50  4 mg/kg IV q24h Not
recommended
25
Triazoles
Itraconazole
fAUC/MIC
Not determined 200 mg PO q24h 0.5–1 (measured
during the ﬁrst
5 days of
therapy and
regularly after)
54
Fluconazole 13–50 400–800 mg/day
PO/IV for
systemic
infections;
1200–2000 mg/day
PO/IV for
cryptococcal
meningitis.
Dosing can be
scheduled q12h
or q24h
Not  used. 12, 13, 39, 44
Voriconazole 11–52 (candidiasis)
80–100 (aspergillosis)
200 mg PO q12h 1–5 (measured
during the ﬁrst
5 days of
therapy and
regularly after)
17
Posaconazole 6–27 (candidiasis)
20 (aspergillosis)
200–600 mg PO
q24h
>0.7
(prophylaxis)
>1 (established
infection)
16,  60
Isavuconazonium
sulfate (prodrug)
34  Loading dose
372 mg q8h × 6
doses, then
372 mg IV q24h
Unknown 45
Echinocandins
Anidulafungin fCmax/MIC
(or
fAUC/MIC)
1 (or 10–20) Loading dose
200 mg IV, then
100 mg IV q24h
Not used 20
Micafungin 1 (or 7.5–30) 150 mg IV q24h Not used 74
Caspofungin 1 (or 10–20) Loading dose Not  used 69molecules, it displays the highest Vd (131 ± 8 L/kg) and fastest
Cl (426 ± 189 mL/h/kg) of all formulations. In contrast, AMBl
has the lowest Vd (0.11 ± 0.08 L/kg) and Cl (11 ± 6 mL/h/kg)
among amphotericin formulations, while AMBcd has a similar
Vd but faster clearance (117 mL/h/kg) than AMBd. Additionally,
as lipid forms accumulate more  in the mononuclear phago-
cytic system and 10-times less in the kidneys, they are less
frequently associated with nephrotoxicity than AMBd.33
Among the lipid formulations, AMBl is the smallest, uni-Please cite this article in press as: Gonzalez JM, et al. Antifungal pharm
http://dx.doi.org/10.1016/j.bjid.2016.09.009
lamellar molecule (60–70 nm vs. 1600–11,000 nm for AMBlc),
achieving the highest Cmax (83 ± 35 mg/L) after a single dose,34
but also displaying the highest protein binding. However, the70 mg IV, then
50 mg IV q24h
small size of AMBl facilitates slightly higher concentrations in
central nervous system compared to other lipid formulations.
In fact, in the central nervous system model of candidiasis,
only AMBl and AMBd sterilized the brain tissue, whereas the
other lipid formulations did not,34 and only AMBd and AMBl
reached detectable cerebrospinal ﬂuid concentrations, with a
transfer rate ranging from 0.02% to 0.92%.35
The clinical correlation of the potential PD differences
among lipid formulations has been difﬁcult to establishacodynamics: Latin America’s perspective. Braz J Infect Dis. 2016.
because there are limitations regarding the MIC  determina-
tion and the differences in the models used to establish
the PK/PD indices. Further, therapeutic monitoring is not
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enerally advocated for AMB  and there are no widely accepted
rug exposure targets. However, the optimal target attainment
as been deﬁned for AMBd as well as AMBl. A PK/PD study in
ine children with fungal infection treated with AMBl found
hat, while a Cmax/MIC = 40 ± 13 produced a partial response,
ull response needed it to be 67.9 ± 17 (p = 0.021).36 Considering
hat AMBd is approximately 5× more  potent than AMBl, these
esults are consistent with the reported value of Cmax/MIC of
0 for maximal efﬁcacy of AMBd.
Cornelly et al. conducted a multicenter randomized
ouble-blind study in patients with probable or demonstrated
old invasive infections. Their study aimed to optimize the
max/MIC with AMBl comparing a 3 mg/kg vs. a 10 mg/kg dose
ased on a previous work that showed that the latter reaches
max > 100 mg/L. No signiﬁcant differences were found in the
lobal clinical response (50% vs. 46%) or survival after 12 weeks
71% vs. 58%), but there was a higher incidence of renal toxicity
16% vs. 30%).37 The absence of clinical beneﬁt of the higher
ose can be explained by the fact that at 3 mg/kg the goal of the
K/PD index required for maximal efﬁcacy has already been
eached, and higher doses only lead to increased toxicity.30
inally, a 999-patient simulation based in the neutropenic-
abbit model of invasive pulmonary aspergillosis showed that
 mg/kg/day of AMBl or 1 mg/kg/day of AMBd was predicted to
esult in near-maximal antifungal activity and suppression of
iomarkers.27 The optimal dose of AMBlc and AMBcd has not
een as clearly established as the AMBd and AMBl.
riazoles
hese fungistatic drugs act blocking the synthesis of ergo-
terol mainly by inhibiting the cytochrome P450 dependent
4- demethylase (CYP51A1), which converts lanosterol into
rgosterol.38,39 These drugs are actually time-dependent, but
hey also exhibit prolonged PAFE, therefore the PD index driv-
ng efﬁcacy is the fAUC/MIC.13,15,17,18,24,40
Fluconazole absorption from the gastrointestinal tract is
lmost complete and unaffected by gastric acidity or food, is
oorly metabolized, and bioavailability is near 100%. Its elim-
nation half-life ranges from 25 to 30 h, it exhibits minimal
rotein binding (12%), and is excreted mainly by the kidneys.
he Cmax obtained after a 100 mg  oral dose was 2 mg/L.41
s ﬂuconazole is a small molecule (MW  = 309) actively dis-
ributed into body ﬂuids (Vd = 46 ± 8 L), the levels attained in
erebrospinal ﬂuid (or even in brain parenchyma) at steady
tate are ≥50% of the concentration observed in plasma. Due
o this PK property, ﬂuconazole is a well-accepted alternative
herapy for cryptococcal (at high doses of 1200–2000 mg/day)
nd Candida meningoencephalitis. Itraconazole, by contrast, is
 large molecule (MW  = 705) highly bound to proteins, exhibit-
ng a cerebrospinal ﬂuid/plasma concentration ratio of ≤0.1242
hat prevent its use in fungal CNS infections.
Regarding ﬂuconazole, Louie et al. demonstrated in the
urine model of systemic candidiasis that the effect of this
rug on the fungal burden was the same when administer-
ng a single dose or dividing it in two or four injections.40Please cite this article in press as: Gonzalez JM, et al. Antifungal pharm
http://dx.doi.org/10.1016/j.bjid.2016.09.009
owever, it should be noted that prolonged periods of expo-
ure below the MIC  might favor resistance of C. albicans
gainst ﬂuconazole.43,44 Multiple studies in vivo with ﬂucona-
ole against several species of Candida along a wide MIC;x  x x(x x):xxx–xxx 5
range have conclusively shown that the fAUC/MIC necessary
to reach 50% of the maximal efﬁcacy (ED50) is between 12.5 and
50.12,13,40 We  determined in the NMDC model that two  vastly
different strains of C. albicans (MIC 0.25 and 4 mg/L) required
fAUC/MIC of 25–38 to attain the ED50.45
The relationship between ﬂuconazole dose, the MIC  of the
infecting agent, and the outcome in patients with mucocu-
taneous candidiasis and candidemia has been addressed in
several papers.12,22,23 Rex et al. published two  decades ago that
the clinical efﬁcacy of ﬂuconazole began to diminish with MIC
above 8 mg/L, but they did not run a PK/PD analysis.22 Later,
Rodriguez-Tudela et al. studied 126 patients with candidemia
and 110 with pharyngeal candidiasis ﬁnding that dose/MIC
ratios of at least 100 (corresponding to fAUC/MIC = 79) pre-
dicted cure for 93% of the subjects.22 In the Latin America
Invasive Mycosis Network, the MIC90 for blood-isolated C.
albicans, C. parapsilosis, and C. tropicalis were ≤1 mg/L3; as those
three strains represent 82% of cases, no more  than 400 mg/day
of ﬂuconazole should be necessary to treat most of patients.
With the other triazoles, similar fAUC/MIC ratios have
been found against several Candida spp.17,18,46 For example,
voriconazole and posaconazole require respectively fAUC/MIC
of 11–52 and 6–27 to reach the ED50 in the NMDC model, while
isavuconazole (protein binding > 95%) required fAUC/MIC of 34
to achieve 90% survival, quite similar to other triazoles. Phar-
macokinetic studies of voriconazole in humans have shown
58% protein binding and nonlinear saturable kinetics, with
the AUC increasing in a higher proportion than the dose. At
doses of 200 mg  PO q12h or 3 mg/kg IV q12h, the fAUC is 20.47
Considering that the target for ED50 is fAUC/MIC around 20
(range 11–50), one could infer that clinical success would be
attained with strains with MIC up to 1 mg/L. This agrees with
the susceptibility breakpoint deﬁned by CLSI, highlighting the
relevance of the PK/PD approach.48 All Candida species iso-
lated in the Latin America Invasive Mycosis Network had a
MIC  ≤ 0.5 mg/L.
The pharmacodynamics of voriconazole has also been
studied in the disseminated aspergillosis model (induced by
intravenous inoculation).49 The fAUC/MIC required for 50%
survival (ED50) was around 12, while for 100% survival (Emax)
it went up to 80–100. Regarding posaconazole, Lepak et al.
assessed its pharmacodynamics against Aspergillus spp. in
the pulmonary invasive aspergillosis model (induced by nasal
instillation),50 ﬁnding that the fAUC/MIC necessary to achieve
the ED50 was 1.8, but at least 10 was required to reach the
Emax. Howard et al. published similar results,51 and Conte
et al. found in a study of pulmonary transplant patients52 that
posaconazole concentration was 50 times higher in alveolar
cells than in serum or epithelial lining ﬂuid. These results sug-
gest that the PK/PD proﬁle of posaconazole is favorable for the
treatment of pulmonary aspergillosis.
There are also pharmacodynamic data with voriconazole
in patients with invasive aspergillosis, a frequent indication
of this drug. The recommended trough levels of voricona-
zole for therapeutic drug monitoring (TDM) correlating with
lower toxicity and better survival outcomes range from 1 to
53acodynamics: Latin America’s perspective. Braz J Infect Dis. 2016.
2 mg/L ; however, a large inter-individual variability in the
kinetics of the drug was observed. In consequence, 25% of
patients achieved trough levels < 1 mg/L and therapy failed,
whilst 31% had levels > 5.5 mg/L and caused toxicity. Based
ARTICLE IN PRESSBJID-655; No. of Pages 9
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on these data, a randomized clinical study was carried out to
assess the impact of TDM of voriconazole in 110 patients with
invasive fungal infections. The trial showed that TDM was
associated with higher efﬁcacy (81% vs. 57%, p = 0.04) and lower
drug discontinuation due to toxicity (4% vs. 17%, p = 0.02).54
These results support the recent recommendations by the
British Society for Medical Mycology indicating TDM for all
patients receiving voriconazole. The goal is to reach trough
levels (Cmin) between 1 and 4–6 mg/L or, ideally, a Cmin/MIC
ratio of 2–5.55
Posaconazole is characterized by a long half-life (approxi-
mately 30 h), saturable absorption at 800 mg/day, high protein
binding (98%), and a long time to reach steady state concen-
trations (10 days).56 It is usually administered as a suspension
twice a day, so the concentration-time curve is almost ﬂat
with very similar peaks and troughs. Among 67 patients with
refractory invasive aspergillosis that received posaconazole
and underwent TDM, it was found that those with peak
(Cmax) and average concentrations (Cavg) of 0.14 and 0.13 mg/L,
respectively, only had 24% response. In contrast, in patients
with Cmax and Cavg of 1.48 and 1.25 mg/L, 75% had a favor-
able response.57 These results support the recommendation
of trough levels > 1 mg/L for patients with established infec-
tions and 0.7 mg/L for prophylaxis.55 The PK of posaconazole
also exhibits high between-subject variability in patients with
hematologic malignancies,58 another reason for TDM. To the
best of our knowledge, there are no clinical studies corre-
lating the fAUC/MIC of posaconazole with clinical outcome,
but considering that 800 mg  per day yields fAUC around
0.30–0.44,52,59 a fAUC/MIC near 3 can be attained with MICs
up to 0.125 mg/L, the EUCAST susceptibility breakpoint for A.
fumigatus.60 To improve bioavailability and reduce between-
subject variability in patients, a delayed-release (DR) tablet
formulation was developed. At a dose of 300 mg  once a day
(three 100 mg  DR tablets), 90% of patients achieved posacona-
zole serum concentrations greater than 700 ng/mL, compared
with 58% patients receiving the oral suspension. Acid sup-
pression did not affect posaconazole levels in the DR tablet
cohort.61
Echinocandins
These are large lipoproteins with negligible oral bioavailabil-
ity, extensive protein binding (>95%), lack of renal clearance,
and no penetration to cerebrospinal ﬂuid. Their unique mech-
anism of action (inhibition of 1,3--glucan synthase), high
in vivo efﬁcacy, and safety proﬁle, has increased its use as
treatment for invasive candidiasis and aspergillosis. The three
approved agents are caspofungin, anidulafungin, and mica-
fungin.
Being the newer group of antifungals, echinocandins have
been studied thoroughly from a PK/PD perspective.62 They
are fungicidal against Candida spp. and fungistatic against
Aspergillus spp. The PD index that best drive their action is
the fCmax/MIC, displaying prolonged PAFE.21,63–65 However, in
the NMDC model, the fAUC/MIC ratio is also a strong predictorPlease cite this article in press as: Gonzalez JM, et al. Antifungal pharm
http://dx.doi.org/10.1016/j.bjid.2016.09.009
of efﬁcacy, presumably due to the prolonged tissue distribu-
tion of these compounds including the kidneys, where the
antifungal effect is measured in this model. Dose fraction-
ation studies have shown that the dose required to reduce 6;x x x(x x):xxx–xxx
the fungal burden by 1 log10 is 4-fold lower when the drugs
are administered once daily.21,62 Of note, a paradoxical effect
consisting in a reduced fungicidal efﬁcacy against Candida spp.
has been observed in vitro at concentrations above the MIC.66
Such effect results of compensatory responses to 1,3--glucan
synthesis and disappears when human serum is added, indi-
cating that it is not likely to impact the treatment of patients
with candidemia.67
The magnitude of PD indices bound to maximal efﬁcacy
in animal models of invasive candidiasis is a fCmax/MIC of
1 or a fAUC/MIC between 10 and 20 for anidulafungin,21
micafungin,62 and caspofungin. Considering that the usual
dose of anidulafungin (200 mg  loading dose followed by
100 mg q24h) is associated with fCmax = 1.15 mg/L and
fAUC = 1.12 mg  h L−1,68 the PD target will be attained against
strains with MIC ≤ 0.125 mg/L. Recent epidemiological stud-
ies indicate that the MIC90 of anidulafungin is <0.125 mg/L
for many  Candida species excepting C. parapsilosis, C. guillier-
mondii, C. lusitaniae and C. famata.69 An in vivo PD study found
that the fAUC/MIC to be fungistatic against C. parapsilosis and
C. glabrata was 7, in contrast to 20 against C. albicans.70 These
data support the CLSI susceptibility breakpoint of 0.25 mg/L
for C. albicans, C. tropicalis, and C. krusei,  and 2 mg/L for C.
parapsilosis.71
The majority of clinical trials with echinocandins have
focused on the evaluation of clinical efﬁcacy72,73 and its rela-
tion to the MIC.74 Regarding micafungin, a PK/PD analysis of
data from 493 patients found that a fAUC/MIC between 7.5
and 30 was associated with 98% microbiological success, com-
pared to 85% when the index was <7.5.75 Finally, in patients
with C. parapsilosis infection, a fAUC/MIC > 0.71 was related to
100% microbiological success compared with 82% in patients
with values < 0.71. This is a further demonstration that C. para-
psilosis requires a 10-fold lesser fAUC/MIC, in line with its
higher susceptibility breakpoint.
Finally, in pediatric patients, dosing adjustment is neces-
sary for most antifungal drugs to obtain the same exposure
achieved in adults. Also, differences are known in drug
metabolism and clearance, and the magnitude of the PK/PD
indices requires more  studies in that speciﬁc population.
Fungal infections in children compared to adults may affect
organs and systems differently (e.g. CNS infection during can-
didemia is frequent in children). A recent review on pediatric
pharmacology of antifungal agents is available.76
Conclusion  and  future  perspectives
Fungal diseases are a growing public health problem.
Although epidemiological data are scant, a prospective sur-
vey shows an incidence of 0.98 per 1000 hospital admissions
in Latin America, approximately four-times the incidence
reported in Europe and North America.77 Medical comor-
bidities and political, economic, and climatic factors are
contributing to increase and to perpetuate the problem.
In addition, antifungal pharmacology knowledge has beenacodynamics: Latin America’s perspective. Braz J Infect Dis. 2016.
progressively increasing, mainly, by the determination of
drug exposure-response relationships. The integration of
PK/PD has facilitated the design of optimal drug regimens
that help maximize efﬁcacy while simultaneously reducing
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oxicity, ameliorating the development of resistance and cut-
ing costs, as corroborated by clinical trials.78 This knowledge
an be applied to each patient in any clinical setting (Table 1),
lthough TDM is necessary to assure that the magnitude of
he PK/PD indices required for maximal efﬁcacy are effec-
ively achieved. This process would introduce an additional
xpenditure related to the quantiﬁcation of drugs in special-
zed laboratories, which could be offset by the much greater
conomic and social beneﬁts of optimized therapy.79
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